Fluticasone Propionate

VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the successful closing of its previously announced public offering (the "Offering") of 14,636,363 common shares of the Company (the “Common Shares"), which includes the full exercise of the option to purchase additional shares granted to the underwriters, at a price to the public of US$5.50 per Common Share for gross proceeds of approximately US$80.5 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the Offering. “This financing represents a pivotal milestone for Eupraxia, enabling us to accelerate the development of EP-104GI for eosinophilic esophagitis and advance toward our upcoming Phase 2b clinical readout, plus other key clinical and regulatory milestones,” said James Helliwell, CEO of Eupraxia. "The strong participation from leading life-science focused investors validates both our strategy and technology, and with this financing, we believe we are now capitalized into the first quarter of 2028, providing the resources and flexibility to deliver on our vision.” Cantor and LifeSci Capital acted as joint book-running managers for the Offering. Bloom Burton also acted as co-manager for the Offering. As previously stated, the Company intends to use the net proceeds from the Offering primarily for the continued advancement of its product pipeline, including the completion of ongoing preclinical studies and clinical trials, regulatory submissions, and associated commercial preparation and manufacturing scale-up activities. A portion of the proceeds will also be allocated to research and development of additional pipeline candidates, business development initiatives, and general corporate purposes, which may include but are not limited to employee salaries, working capital, leases for facilities, administrative expenses, and capital expenditures. The Company may also use a portion of the proceeds to expand its intellectual property portfolio and strengthen its corporate infrastructure to support future growth. The Offering was made pursuant to a U.S. registration statement on Form F-10, declared effective by the U.S. Securities and Exchange Commission (the "SEC") on February 7, 2024, and the Company's existing Canadian short form base shelf prospectus, (the "Base Prospectus") dated February 5, 2024. A preliminary prospectus supplement and a final prospectus supplement (the “Supplement”) relating to and describing the terms of the Offering were filed with the securities commissions in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States. The Supplement and accompanying Base Prospectus contain important detailed information about the Offering. The Supplement and accompanying Base Prospectus can be found on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Copies of the Supplement and accompanying Base Prospectus may also be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com, from LifeSci Capital LLC at 1700 Broadway, 40th Floor, New York, New York 10019, or by email at compliance@lifescicapital.com, or from Bloom Burton Securities Inc. at ecm@bloomburton.com. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction. About Eupraxia Pharmaceuticals Inc. Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. Notice Regarding Forward-looking Statements and Information This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "suggests", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the anticipated use of proceeds from the Offering; expectations around the development of EP-104GI, upcoming Phase 2b clinical trial readouts, and other clinical and regulatory milestones; expected capitalization into the first quarter of 2028; and the potential for the Company’s technology to impact the drug delivery process. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company’s active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise. For investor and media inquiries, please contact:Danielle Egan, Eupraxia Pharmaceuticals Inc.778.401.3302degan@eupraxiapharma.com or Kevin Gardner, on behalf of:Eupraxia Pharmaceuticals Inc.617.283.2856kgardner@lifesciadvisors.com SOURCE Eupraxia Pharmaceuticals Inc.

“ 点击蓝字 关注我们 丙酸氟替卡松联合特布他林与异丙托溴铵雾化治疗儿童哮喘急性发作的效果 PPS  姜平 1，姚培燕 2，赵兰玉 1，李春娥 1，沈怡 1* （1. 复旦大学附属闵行医院儿科 上海市闵行区中心医院儿科，上海 201100；2. 上海市闵行区莘庄社区卫生服务中心儿科全科，上海201199） [摘要] 目的 分析丙酸氟替卡松联合特布他林、异丙托溴铵雾化吸入疗法在儿童哮喘急性发作中的应用效果。 方法 选择复旦大学附属闵行医院门诊、哮喘专病门诊和莘庄社区卫生服务中心儿科门诊于 2024 年 1 月至 2025 年 2 月收治的 100 例哮喘急性发作患儿为研究对象，按照随机数表法分为研究组及对照组，各 50 例。对照组采用醋酸泼尼松片联合特布他林及异丙托溴铵雾化治疗，研究组采用丙酸氟替卡松联合特布他林及异丙托溴铵雾化治疗，两组均持续治疗 7 d。比较两组患儿治疗 7 d 后的临床疗效，治疗前及治疗 7 d 后的肺功能，肺泡气一氧化氮浓度（concentration of alveolar nitric oxide，CaNO），呼出气一氧化氮（fractional exhaled nitric oxide， FeNO），临床症状评分，并观察患儿的临床症状消失时间及不良反应。 结果 治疗 7 d 后，两组的临床总有效率无差异（单侧P ＞ 0.05）。治疗前，两组患儿肺功能、CaNO、FeNO 和临床症状评分比较均无差异（双侧P ＞ 0.05）；治疗 7 d 后，两组患儿的肺功能指标均提高， CaNO、FeNO 水平均下降，但组间无差异（双侧P ＞ 0.05），两组治疗后的日间和夜间临床症状评分均下降，但组间无差异（双侧P ＞ 0.05）。研究组的临床症状消失时间均早于对照组（双侧P ＜ 0.05）。研究组的不良反应总发生率低于对照组（单侧P ＜ 0.05）。结论 丙酸氟替卡松联合特布他林、异丙托溴铵雾化治疗儿童哮喘急性发作的有效性高，能改善患儿的肺功能，降低 CaNO 及 FeNO 水平，缩短患儿的临床症状消失时间，并能减少药物不良反应。  儿童哮喘急性发作的病情危急，雾化吸入疗法是目前治疗儿童哮喘急性发作的有效手段，起效快速，且不易引起全身不良反应 [1]。特布他林及异丙托溴铵均是儿童哮喘的常用雾化药，其中特布他林是短效 β2 受体激动剂，能迅速缓解支气管痉挛，改善气道阻力；异丙托溴铵是抗胆碱药物，能通过抑制迷走神经活性扩张气道，二者联合具有协同扩张支气管作用 [2]。但二者联合无法从根本上缓解气道炎症，还需结合其他抗炎治疗 [3]。糖皮质激素具有强效的抗炎作用，能通过多途径抑制气道炎症反应，提高治疗急性哮喘的效果。丙酸氟替卡松是类固醇药物，与口服糖皮质激素不同，其通过雾化吸入的方式直接作用于肺部，减少气道炎症 [4]。临床研究表明，丙酸氟替卡松治疗能显著提高儿童哮喘急性发作的临床疗效，并改善长期控制效果 [5]。丙酸氟替卡松联合特布他林、异丙托溴铵具有抗炎与支气管扩张的双重作用，理论上，在快速缓解症状的同时，能有效抑制气道炎症，降低复发率，提高治疗安全性和依从性。但临床关于以上药物联合应用的研究较少，因此本研究主要探讨丙酸氟替卡松联合特布他林与异丙托溴铵的雾化吸入疗法在儿童哮喘急性发作中的应用效果。  1 对象与方法  1.1 研究对象 样本量按照总有效率，通过均数计数公式n=P1× （ 1-P1）＋ P2×（ 1-P2）÷（ P2-P1）2×（μα ＋ μβ）2进行计算，取 α = 0.05， β = 0.10，则 μα = 1.96， μβ = 1.28，对照组的总有效率为 92.00%（ 46/50），研究组的总有效率为 94.00%（47/50）， n=[（0.94×0.13）＋（0.92×0.37）]×（1.96 ＋ 1.28）2÷（0.94-0.92）2，得出 n=48，通过 1∶1 比例进行分组，每组至少 96 例，实际总共纳入 100 例。根据测算结果，选择复旦大学附属闵行医院门诊、哮喘专病门诊和莘庄社区卫生服务中心儿科门诊于 2024 年 1 月至 2025 年2 月收治的 100 例哮喘急性发作患儿为研究对象，进行优劣性随机对照研究。纳入标准：①临床明确诊断为哮喘急性发作期，符合《儿童支气管哮喘规范化诊治建议（ 2020 年版）》 [6] 有关支气管哮喘的诊断标准；②急性发作时间在 24 h 以内； ③病情程度为中度；④门诊进行规范雾化吸入疗法；⑤年龄 6 ~ 14 岁；⑥患儿家属知情同意。排除标准：①由于其他因素引起呼吸困难；②合并其他未控制的严重全身性疾病；③合并呼吸衰竭、呼吸功能严重不全；④近期接受过茶碱类、糖皮质激素治疗；⑤对本研究药物过敏或存在禁忌证。根据随机数表法对患者进行分组，分为各 50 例的研究组与对照组，两组临床资料经比较，均无统计学差异（ P ＞ 0.05），见表 1。本研究获得患儿家属知情同意，且经过医院伦理委员会批准（审批号： 2023- 批件-066-01K）。 1.2 方法 对照组用醋酸泼尼松片联合特布他林及异丙托溴铵雾化治疗，前 4 d 口服醋酸泼尼松片（天津信谊津津药业有限公司，国药准字 H31020675，规格： 5 mg/ 片） 2 mg · kg-1 · d-1，最大剂量为 40 mg · d-1；后 3 d 口服醋酸泼尼松片 1/2 初始剂量或 1 mg · kg-1 · d-1，最大剂量为 20 mg · d-1，每天 1 次。雾化吸入 500 μg 异丙托溴铵雾化液（武汉先路医药科技股份有限公司，国药准字 H20213486，规格： 2 mL∶ 0.5 mg）＋ 2.5 mg 特布他林雾化液（南京恒道医药科技股份有限公司，国药准字 H20223363，规格： 2 mL∶ 5 mg）＋ 2 mL 生理盐水，早晚各 1 次，治疗 7 d。 研究组采用丙酸氟替卡松联合特布他林及异丙托溴铵雾化治疗，雾化吸入 500 μg 异丙托溴铵雾化液＋2.5~5 mg 特布他林雾化液＋ 2 mL 生理盐水；雾化吸入500 μg 丙酸氟替卡松（GlaxoSmithKline Australia Pty Ltd.，国药准字 HJ20170361，规格： 2 mL∶ 0.5 mg）＋2 mL 生理盐水，早晚各 1 次，治疗 7 d。 1.3 观察指标 1.3.1 临床疗效 [6] 治疗 7 d 后评估临床疗效。肺部未见哮鸣音，临床症状基本消失为痊愈；肺部见少许呼气末期哮鸣音，临床症状显著减轻为显效；肺部提示散在哮鸣音，临床症状有所好转为有效；临床症状未见明显减轻或并无改变，甚至肺部存在弥漫、响亮的双相哮鸣音为无效。将痊愈例数＋显效例数＋有效例数计入总有效中。 1.3.2 肺功能 用 HI-101 肺功能检测仪于治疗前及治疗 7 d 后测量用力肺活量（ forced vital capacity，FVC）、 第 一 秒 用 力 呼 气 容 积（forced expiratory volume in one second， FEV1）。 1.3.3 肺泡气一氧化氮浓度（ concentration of alveolar nitric oxide， CaNO）、呼出气一氧化氮（ fractional exhaled nitric oxide， FeNO） 治疗前及治疗 7 d 后由呼气分析仪测量 CaNO 及 FeNO 值。 1.3.4 临床症状评分 [7] 治疗前及治疗 7 d 后用哮喘症状评分评估患儿临床症状，日间症状评分 0~ 5 分，夜间症状评分 0~ 4 分，症状越重分数越高。 1.3.5 临床症状 记录患儿肺部哮鸣音、发热、胸闷、气促、咳嗽、喘息消失的时间。 1.3.6 不良反应 记录患儿治疗期间发生的不良反应。 1.4 统计学方法 采用 SPSS 26.0 软件进行数据分析。肺功能、临床症状评分等计量资料用均数 ± 标准差（x̄±s）表示，采用两个因素的多重组间比较；性别、哮喘严重程度等计数资料用率表示，比较采用 χ2检验。P ＜ 0.05 表示有统计学意义。 2 结果  2.1 两组临床疗效对比  两组临床总有效率经对比，未见统计学差异（P ＞ 0.05），见表 2。 2.2两组肺功能、CaNO、FeNO 对比 治疗 7 d 后，两组肺功能指标均提高， CaNO、FeNO 水平均下降，但组间无差异（双侧 P ＞ 0.05），见表 3。 2.3 两组临床症状评分对比 治疗 7 d 后，两组日间和夜间临床症状评分均下降，但组间无差异（双侧 P ＞ 0.05），见表 4。 2.4 两组临床症状消失时间对比 研究组的临床症状消失时间均早于对照组（双侧 P ＜ 0.05），见表 5。 2.5 两组不良反应对比 研究组不良反应总发生率低于对照组（P ＜ 0.05），见表 6。 3 讨论  儿童哮喘迁延难愈，易反复发作，其中急性发作期是儿童哮喘的高风险阶段，若未及时干预，可能导致严重并发症 [8-9]。儿童急性哮喘发作的治疗目的是尽快控制急性发作，缓解症状及预防复发 [10]。 雾化吸入具有局部治疗作用，药物通过气道能快速进入肺部，起到治疗作用。特布他林是缓解哮喘发作症状的首选药物，其作为短效 β2 受体激动剂，通过激活 β2 受体，增加细胞内环磷酸腺苷水平，促进平滑肌松弛，降低气道阻力，改善通气状态，缓解哮喘症状 [11]。异丙托溴铵多与短效 β 受体激动剂联合雾化吸入，其作为抗胆碱能药物，能抑制副交感神经系统中的 M3 受体，减少气道平滑肌的收缩，起到扩张气道的作用 [12]。尽管特布他林和异丙托溴铵在哮喘急性发作中有显著效果，但其主要作用是缓解气道痉挛及扩张气道，对气道炎症的作用不明显。 有研究 [13] 表示，糖皮质激素能够显著减轻哮喘急性发作期的患儿气道炎症，快速恢复气道功能。口服醋酸泼尼松片可通过系统性作用控制全身的免疫炎症反应，但其起效较慢，且不良反应较多 [14]。丙酸氟替卡松是吸入型糖皮质激素，经雾化吸入的方式，能更精准地作用于气道，具有显著抗炎效果，并减少全身性不良反应。丙酸氟替卡松能抑制前列腺素、白三烯等炎症介质合成，减少气道炎症反应，并能减少气道的免疫反应性，降低气道的高反应性，减少过敏症状的发生 [15]。在特布他林及异丙托溴铵雾化吸入疗法的基础上联合丙酸氟替卡松能快速缓解哮喘急性发作的症状，并有效降低气道的炎症反应。本研究显示，丙酸氟替卡松雾化组与醋酸泼尼松组总有效率相似，提示丙酸氟替卡松雾化吸入能起到与口服醋酸泼尼松类似的治疗效果，与王娇等 [16] 的研究结果一致，该研究表示，吸入性糖皮质激素对控制儿童哮喘急性发作的疗效是肯定的，且不良反应较少。原因主要是，特布他林及异丙托溴铵均能快速缓解急性哮喘发作的气道痉挛；丙酸氟替卡松与醋酸泼尼松均是糖皮质激素，可抑制气道炎症反应，减少气道的免疫反应性，长期降低气道的过敏性，提高治疗效果。哮喘急性发作患儿气流受限较明显，且普遍肺功能显著下降。 CaNO及 FeNO 作为反映气道炎症及气道重构的生物标志物，在哮喘急性发作期的水平也显著上升。本研究显示，两种治疗方法均能显著改善患儿的肺功能，降低 CaNO 及 FeNO 水平、临床症状评分。李予鄂等 [17]的对比研究也显示，吸入型糖皮质激素能有效降低FeNO 水平。主要是因为，特布他林及异丙托溴铵能快速缓解支气管痉挛，降低气道阻力，改善气道通畅性，从而改善肺功能指标。丙酸氟替卡松及醋酸泼尼松均能有效抑制气道炎症，降低气道的免疫反应性，降低 CaNO 及 FeNO 水平，进一步改善肺功能，减轻临床症状。但本研究显示，联合丙酸氟替卡松雾化吸入更能加速患儿的临床症状消失时间（ P ＜ 0.05）。分析原因为，特布他林和异丙托溴铵能快速缓解气道痉挛，同时丙酸氟替卡松具有强效的抗炎作用，其通过雾化吸入给药能直接作用于气道，缩短炎症反应的时间，在短期间内改善临床症状。而醋酸泼尼松作为口服糖皮质激素，吸收及发挥作用的时间较长，因此症状的缓解时间更久。 本研究中，丙酸氟替卡松雾化吸入组患儿的不良反应总发生率较对照组更低（ P ＜ 0.05），主要是因为，丙酸氟替卡松通过雾化吸入给药，能减少全身性不良反应的发生。而口服醋酸泼尼松在体内全身吸收，导致全身不良反应的发生率更高。相关研究也表示，吸入型糖皮质激素长期使用的安全性良好，可用于儿童 [18]。本研究仅观察了 6~14 岁年龄阶段的患儿，今后研究建议纳入其他年龄段的患儿，更全面地观察丙酸氟替卡松雾化吸入在儿童哮喘治疗中的效果。 综上所述，丙酸氟替卡松联合特布他林、异丙托溴铵雾化吸入疗法儿童哮喘急性发作中使用安全有效，能改善患儿的肺功能，降低 CaNO 及 FeNO水平，缩短患儿的临床症状消失时间。 参考文献： [1]     陈福将, 吴超雄, 何丽丹, 等. 吸入用复方异丙托溴铵溶液雾化吸入治疗儿童哮喘急性发作的临床研究 [J]. 中国临床药理学杂志, 2023, 39(11): 1523-1527.[2]路鑫畅, 范扬, 李娜. 异丙托溴铵联合甲强龙对小儿支气管哮喘急性发作期呼气一氧化氮和免疫球蛋白 E 水平的影响 [J]. 中国妇幼保健, 2024, 39(18): 3518-3521. [3]Dhochak N, Kabra S K. Challenges in the management of childhood asthma in the developing world[J]. Indian J Pediatr, 2022, 89(2): 169-173. [3]黄伟瑜, 谢毅勇, 方伟杰. 维生素 A 制剂辅以丙酸氟替卡松吸入气雾剂治疗儿童支气管哮喘的效果及对患儿体液免疫功能和肺功能的影响 [J]. 中国妇幼保健, 2023, 38(24): 4852-4855. [5]程琪, 张晗, 尚云晓, 等. 丙酸氟替卡松雾化吸入用混悬液在 2 ~ 4岁哮喘儿童急性发作期的有效性和安全性多中心临床研究 [J].中国实用儿科杂志, 2023, 38(11): 846-852. [6]中华儿科杂志编辑委员会, 中华医学会儿科学分会呼吸学组, 中国医师协会儿科医师分会儿童呼吸专业委员会. 儿童支气管哮喘规范化诊治建议（ 2020 年版） [J]. 中华儿科杂志, 2020, 58(9): 708-717. [7]邹晓东, 王伟, 黄绍光. 哮喘症状评分临床应用价值 [J]. 现代诊断与治疗, 1993, 4(3): 284-286. [8]Laubhahn K, Phelan K J, Jackson D J, et al. What have mechanistic studies taught us about childhood asthma?[J]. J Allergy Clin Immunol Pract, 2023, 11(3): 684-692. [9]Jones H, Lawton A, Gupta A. Asthma attacks in children: challenges Indian J Pediatr, 2022, 89(4): 373-377. [10] Mahesh S, Ramamurthy M B. Management of acute asthma in children[J]. Indian J Pediatr, 2022, 89(4): 366-372. [11]东雪洁, 贾广媛, 张葆青, 等. 清咳平喘颗粒联合布地奈德和硫酸特布他林治疗小儿支气管哮喘急性发作期（热哮证）的疗效观察 [J]. 现代药物与临床, 2023, 38(5): 1142-1146. [12] Wongwaree S, Daengsuwan T. Comparison efficacy of randomized nebulized magnesium sulfate and ipratropium bromide/ fenoterol in children with moderate to severe asthma exacerbation[J]. Asian Pac J Allergy Immunol, 2022, 40(1): 31-38. [13] 尉耘翠, 王舒, 何晓静, 等. 糖皮质激素雾化吸入混悬液应用于儿童哮喘急性期综合评价 [J]. 儿科药学杂志, 2023, 29(11): 35- 43. [14] Shamji M H, Boyle R J. Management of childhood asthma and tools to evaluate asthma pathophysiology[J]. Clin Exp Allergy, 2023, 53(11): 1138-1140. [15]陈丽芳, 黎小年, 王佩. 维生素 D 联合丙酸氟替卡松吸入气雾剂治疗小儿支气管哮喘的疗效及对血清 IgA、 IgE 水平的影响 [J].临床和实验医学杂志, 2023, 22(7): 734-738. [16]王娇, 王雪艳. 吸入性糖皮质激素联合福莫特罗在哮喘维持和缓解治疗中的应用价值 [J]. 国际儿科学杂志, 2025, 52(1): 17-21. [17]    李予鄂, 李明. 吸入性糖皮质激素治疗小儿支气管哮喘的临床疗效及对血清炎性因子的影响 [J]. 微循环学杂志, 2023, 33(1): 48- 51. [18]黄莉萍, 卢姝亚, 彭东红. 沙美特罗/丙酸氟替卡松与丙酸氟替卡松在儿童哮喘升阶梯治疗中有效性及安全性的系统评价和 Meta分析 [J]. 中国循证儿科杂志, 2023, 18(5): 355-361. 美编排版：覃冰冰 感谢您阅读《药学进展》微信平台原创好文，也欢迎各位读者转载、引用。本文选自《药学进展》2025年第 7 期。 《药学进展》杂志由教育部主管、中国药科大学主办，中国科技核心期刊（中国科技论文统计源期刊）。刊物以反映药学科研领域的新方法、新成果、新进展、新趋势为宗旨，以综述、评述、行业发展报告为特色，以药学学科进展、技术进展、新药研发各环节技术信息为重点，是一本专注于医药科技前沿与产业动态的专业媒体。 《药学进展》注重内容策划、加强组稿约稿、深度挖掘、分析药学信息资源、在药学学科进展、科研思路方法、靶点机制探讨、新药研发报告、临床用药分析、国际医药前沿等方面初具特色；特别是医药信息内容以科学前沿与国家战略需求相合，更加突出前瞻性、权威性、时效性、新颖性、系统性、实战性。根据最新统计数据，刊物篇均下载率连续三年蝉联我国医药期刊榜首，复合影响因子1.216，具有较高的影响力。 《药学进展》编委会由国家重大专项化学药总师陈凯先院士担任主编，编委由新药研发技术链政府监管部门、高校科研院所、制药企业、临床医院、CRO、金融资本及知识产权相关机构近两百位极具影响力的专家组成。 联系《药学进展》↓↓↓ 编辑部官网：pps.cpu.edu.cn； 邮箱：yxjz@163.com； 电话：025-83271227。 欢迎投稿、订阅！ 往期推荐 聚焦“兴药为民·2023生物医药创新融合发展大会”“兴药为民·2023生物医药创新融合发展大会”盛大启幕！院士专家齐聚杭城，绘就生物医药前沿赛道新蓝图“兴药强刊”青年学者论坛暨《药学进展》第二届青年编委会议成功召开“兴药为民·2023生物医药创新融合发展大会”路演专场圆满收官！校企合作新旅程已启航 我知道你在看哟